Expression of target molecules in lung cancer: Challenge for a new treatment paradigm

被引：8

作者：

Hirsch, FR

Franklin, WA

Bunn, PA

机构：

[1] Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA

[2] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA

[3] Univ Colorado, Ctr Canc, Denver, CO 80262 USA

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 03期

关键词：

D O I：

10.1053/sonc.2002.34265

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2 / 8

页数：7

共 46 条

[1]

Achiwa H, 1999, CLIN CANCER RES, V5, P1001

[2]

Adjei AA, 2000, CANCER RES, V60, P1871

[3]

ADJEI AA, 2001, P AN M AM SOC CLIN, V20, P320

[4]

Arteaga CL, 2001, J CLIN ONCOL, V19, p32S

[5] ZD1839 ('Iressa')1,2 as an anticancer agent [J].

Baselga, J ;

Averbuch, SD .

DRUGS, 2000, 60 (Suppl 1) :33-40

[6] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].

Baselga, J ;

Pfister, D ;

Cooper, MR ;

Cohen, R ;

Burtness, B ;

Bos, M ;

D'Andrea, G ;

Seidman, A ;

Norton, L ;

Gunnett, K ;

Falcey, J ;

Anderson, V ;

Waksal, H ;

Mendelsohn, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914

[7] Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis [J].

Belinsky, SA ;

Nikula, KJ ;

Palmisano, WA ;

Michels, R ;

Saccomanno, G ;

Gabrielson, E ;

Baylin, SB ;

Herman, JG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11891-11896

[8]

BOS JL, 1989, CANCER RES, V49, P4682

[9]

Bunn PA, 2001, CLIN CANCER RES, V7, P3239

[10]

BUNN PA, 2001, P AM SOC CLIN ONCOL, P391

← 1 2 3 4 5 →